Oral finafloxacin: Phase II data

Data from 193 patients with cUTI in the mITT population of a double-blind, double-dummy, European Phase II trial showed that 5- and 10-day regimens of once-daily 800 mg finafloxacin each met the primary endpoint of improving the composite response rate, defined as both microbiological eradication and elimination of clinical symptoms, at the TOC visit 17 days after the start of treatment vs. twice-daily 400 mg ciprofloxacin for 10 days, the standard of care (70% and 68%, respectively, vs. 57%). On secondary endpoints, finafloxacin improved the proportion of patients who achieved microbiological eradication 3 days after the start of treatment vs. ciprofloxacin (89% vs. 79%). Additionally, a greater proportion of patients receiving the 5-day finafloxacin regimen achieved microbiological eradication 24 days after the start of treatment vs. ciprofloxacin (75% vs. 59%). Finafloxacin was well tolerated. ...